Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.63 |
| ▸ | ACHE | P22303 | 4/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flortaucipir SCHEMBL29548430 | 0.84 | MAPT (0.77) | MAPTACHEKIF11 | |
| Flortaucipir SCHEMBL14053964 | 0.84 | MAPT (0.77) | MAPTACHEKIF11 | |
| Flortaucipir SCHEMBL29439901 | 0.84 | MAPT (0.77) | MAPTACHEKIF11 | |
| Flortaucipir F 18 SCHEMBL13640613 | 0.84 | MAPT (0.77) | MAPTACHEKIF11 | |
| Flortaucipir F 18 SCHEMBL29707635 | 0.84 | MAPT (0.77) | MAPTACHEKIF11 | |
| Flortaucipir F 18 SCHEMBL29379518 | 0.84 | MAPT (0.77) | MAPTACHEKIF11 | |
| Flortaucipir SCHEMBL29773835 | 0.84 | MAPT (0.77) | MAPTACHEKIF11 | |
| SCHEMBL16610292 | 0.84 | MAPT (0.63) | MAPTACHEKIF11PDE10ATLR9 | |
| SCHEMBL23418077 | 0.83 | MAPT (0.60) | MAPTACHEKIF11TLR9TLR8 | |
| SCHEMBL22906814 | 0.83 | MAPT (0.60) | MAPTACHEKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210047321-A1 | GAMMA-CARBOLINE COMPOUNDS FOR THE DETECTION OF TAU AGGREGATES | Lantheus Biosciences Ltd. (GB) | 2021-02-18 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-3092243-B1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | CENTRE NAT RECH SCIENT (FR) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018144649-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | Arvinas, Inc. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-11-10 | — | — | US | disclosed |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-11-10 | — | — | US | disclosed |
| US-20160228586-A1 | Compounds and Their Use for Preparation of Tau Imaging Agents and Tau Imaging Formulations | LILLY CO ELI (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | MAPT 1/4885ACHE 3025/4885KIF11 2516/4885 |
| US-20160228586-A1 | Compounds and Their Use for Preparation of Tau Imaging Agents and Tau Imaging Formulations | MAPT, PSEN1, PSEN2 | MAPT 1/4885ACHE 688/4885KIF11 54/4885 |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | KIT, NISCH, FLT3 | MAPT 1818/4885ACHE 964/4885KIF11 541/4885 |
| US-20210047321-A1 | GAMMA-CARBOLINE COMPOUNDS FOR THE DETECTION OF TAU AGGREGATES | MAPT, PSEN1, PSEN2 | MAPT 1/4885ACHE 355/4885KIF11 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.